Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

Taiho is parting with $400 million upfront for Araris, a spin-off from the Paul-Scherrer-Institute in Zurich, Switzerland, ...

So far, neither Kennedy nor Trump has announced a real effort to make a pharma advertising ban a reality. But it’s hard to ...

The Japanese pharma company – currently in the process of rolling out new amyloid-targeting Alzheimer's therapy Leqembi ...

AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

Measles cases in the European region doubled to 127,350 in 2024, reaching the highest level in nearly three decades and ...

As Global SME of Life Science and Pharma at Tive, Alex Guillen leads sales and business development within the company's rapid-growth life sciences division. Previously, Guillen served as a Board ...

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) had been scheduled to meet to discuss the strains ...

At Veeva Commercial Summit late 2024, web editor Nicole Raleigh spoke with Veeva Systems’ president of Europe, Chris Moore, for a discursive dive into the life sciences during the year.

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...